Literature DB >> 16709040

Novel therapies for malignant gliomas: a local affair?

Nikolai G Rainov1, A Söling, V Heidecke.   

Abstract

Advances in medical and surgical treatments in the last few decades have resulted in quantum leaps in the overall survival of patients with malignant disease outside the central nervous system, whereas survival of patients with malignant gliomas (World Health Organization Grades III and IV) has remained essentially unchanged. Resection and external-beam fractionated radiotherapy remain the pillars of therapy for malignant gliomas and have shown significant beneficial effects on outcome in many clinical studies. On the other hand, numerous human trials with adjuvant agents, most of them administered systemically and causing serious complications and side effects, have not succeeded in achieving a noteworthy additional extension of survival duration, or have done so only with a considerable deterioration in the quality of life of the treated patients. The concept of local invasiveness of gliomas is not new, but only in the last one to two decades has significant attention been focused on the cell biology and molecular genetics of gliomas. Improved understanding of the fundamental features of tumor cells has resulted in the introduction and increasing clinical use of local therapies in which practitioners opt for spatially defined delivery methods and tumor-selective agents specifically designed to be used in the environment of a brain invaded by glioma. In this review, the authors summarize the key findings in some of the most important clinical studies of locally administered treatments for malignant glioma. A few such therapies have emerged in the last decade, and have shown considerable antitumor activity and a favorable profile of local and systemic side effects. These include biodegradable polymers for interstitial chemotherapy, targeted toxins administered by convection-enhanced delivery, and intra- and peritumorally injected genetically modified viruses conferring glioma-selective toxicity. In addition, areas of possible improvement of these therapies and essential further developments are outlined.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709040

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  4 in total

1.  Time-reversal Techniques in Ultrasound-assisted Convection-enhanced Drug Delivery to the Brain: Technology Development and In Vivo Evaluation.

Authors:  George K Lewis; Sabrina Guarino; Gaurav Gandhi; Laurent Filinger; George K Lewis; Willam L Olbricht; Armen Sarvazyan
Journal:  Proc Meet Acoust       Date:  2011-07-10

2.  Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.

Authors:  Karen A Oliveira; Tharine Dal-Cim; Flávia G Lopes; Fabiana K Ludka; Cláudia B Nedel; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

3.  Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.

Authors:  Clovis O da Fonseca; Marcela Simão; Igor R Lins; Regina O Caetano; Débora Futuro; Thereza Quirico-Santos
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-18       Impact factor: 4.553

4.  Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model.

Authors:  Jérôme Côté; Veronica Bovenzi; Martin Savard; Céléna Dubuc; Audrey Fortier; Witold Neugebauer; Luc Tremblay; Werner Müller-Esterl; Ana-Maria Tsanaclis; Martin Lepage; David Fortin; Fernand Gobeil
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.